Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 169

  • 3 924 clinical trials
  • 1 545 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 924 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 924 clinical trials

Cardiac failure+1

Not recruiting

Preventing Heart Failure in Early Breast Cancer Patients Receiving Anthracycline Therapy with Sacubitril and Valsartan (LCZ696)

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Valsartan
  • Sponsor:Akershus University Hospital

Breast cancer

Not recruiting

Study of alpelisib with trastuzumab and pertuzumab as maintenance therapy in adult patients with HER2‑positive advanced breast cancer and PIK3CA mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Plasma cell myeloma refractory

Not recruiting

A Phase 2 Study of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Janssen Cilag International

Chronic rhinosinusitis with nasal polyps

Not recruiting

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Small cell lung cancer extensive stage

Not recruiting

Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Prostate cancer metastatic

Not recruiting

A study to evaluate the safety and effectiveness of AZD9750 and saruparib in patients with metastatic prostate cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Saruparib
  • Sponsor:AstraZeneca AB

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Amgen Inc.

Neoplasm

Not recruiting

A study to compare using a half dose of iomeprol versus a standard dose of iomeprol for imaging lung tumors with spectral CT scans.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Fundacion De La Comunitat Valenciana Para La Gestion Del Instituto De Investigacion Sanitaria Y Biomedica De Alicante

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Basal cell carcinoma

Not recruiting

A study to evaluate the safety and effectiveness of BO-112 injections in patients with resectable primary basal cell carcinoma.

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Highlight Therapeutics S.L.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Infliximab65 clinical trialsVincristine Sulfate55 clinical trialsAbemaciclib45 clinical trialsIbrutinib43 clinical trialsTrifluridine31 clinical trialsAvelumab30 clinical trialsApalutamide27 clinical trialsAmivantamab25 clinical trialsZanubrutinib24 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.